Concepedia

Author

Jean El Cheikh

Institut Paoli-CalmettesORCID

Also Known As

El Cheikh, Jean, J El Cheikh, J El-Cheikh, J El-cheikh, J el Cheikh, J. E. Cheikh, J. El Cheikh, J. El-Cheikh, J. El‐Cheikh, J. el Cheikh

378

Publications

4.4K

Citations

37

H-Index

65

Concepts

All Affiliations

Institut Paoli-CalmettesInsermSorbonne UniversitéHôpital Saint-AntoineAmerican University of Beirut Medical Center
JE

About

Jean El Cheikh is an author at Institut Paoli-Calmettes specializing in medicine, hematology, and cell transplantation.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

26

43

1.5K

2

Blood Transplantation

13

15

575

3

Health Sciences

11

12

490

4

Cell Biology

5

5

201

5

Biomedical Engineering

1

1

13

Jean El Cheikh

×

76

Publications

3K

Citations

34

H-Index

YearCitations

Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies

Gandhi Damaj, Alain Duhamel, Marie Robin,

Journal of Clinical Oncology

2012

204

Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide

Luca Castagna, Roberto Crocchiolo, Sabine Fürst,

Biology of Blood and Marrow Transplantation

2014

153

Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms‐like tyrosine kinase 3‐mutated acute myeloid leukemia

Giorgia Battipaglia, Annalisa Ruggeri, Radwan Massoud,

Cancer

2017

107

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells

Michael Lioznov, Jean El Cheikh, Franz Albert Hoffmann,

Bone Marrow Transplantation

2009

99

CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies

Evgeny Klyuchnikov, Jean El Cheikh, Andreas Sputtek,

Biology of Blood and Marrow Transplantation

2013

91

Haploidentical T Cell–Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen–Matched Related or Unrelated Donor

Didier Blaise, Sabine Fürst, Roberto Crocchiolo,

Biology of Blood and Marrow Transplantation

2015

88

Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors

Rémy Duléry, Anne‐Lise Ménard, Sylvain Chantepie,

Biology of Blood and Marrow Transplantation

2018

84

The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT

Raynier Devillier, Roberto Crocchiolo, Luca Castagna,

Bone Marrow Transplantation

2012

70

Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma

Hugues de Lavallade, Jean El Cheikh, Catherine Faucher,

Bone Marrow Transplantation

2008

68

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

Mohamed Sobh, Mauricette Michallet, Gösta Gahrton,

Leukemia

2016

68

Page 1